Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results for the first nine months of 2023 and business progress for the third quarter of 2023. Revenue for the first nine months increased by 148% to DKK 4,615 million compared to the same period last year, while the operating profit (EBITDA) increased to DKK […]
continue readingBavarian Nordic to Host Third Quarter 2023 Results Conference Call and Webcast
Bavarian Nordic A/S (OMX: BAVA) will announce its 2023 third quarter results on Thursday, November 16, 2023. The management of Bavarian Nordic will host a conference call at 2:00 pm CET (8:00 am EST) on the same day to present the interim results followed by a Q&A session. A listen-only version of the call and […]
continue readingBavarian Nordic Awarded Another Contract to Supply Smallpox Vaccines for EU Strategic Reserve
Bavarian Nordic A/S (OMX: BAVA) announced today, that it has been awarded another contract valued at more than EUR 11 million to supply its MVA-BN® smallpox vaccine to rescEU, a strategic reserve within the European Union (EU). This order follows an initial contract awarded in June 2023 and is also for delivery in 2024. The vaccines will be […]
continue readingBavarian Nordic Receives USD 120 Million Contract for the Manufacturing of Smallpox and Mpox Vaccine from the U.S. Government
Contract award will support manufacturing of new bulk vaccine to partly replenish the inventory used for the mpox outbreak in 2022 Aims to strengthen the long-term U.S. stockpiling of smallpox vaccines Company upgrades its financial guidance for 2023 Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. Biomedical Advanced Research and Development Authority […]
continue readingBavarian Nordic Publishes Annual Report 2022
Bavarian Nordic A/S (OMX: BAVA) today published its Annual Report for 2022. The consolidated, audited results were in line with the preliminary results, announced on January 16, 2023. The full report is attached as a PDF file and can be found on the company’s website, www.bavarian-nordic.com. Paul Chaplin, President & Chief Executive Officer of Bavarian […]
continue readingBavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its COVID-19 Booster Vaccine Candidate
First subject vaccinated in Phase 3 clinical trial evaluating potential of the VLP-based candidate, ABNCoV2 as a booster COVID-19 vaccine Trial will assess non-inferiority of ABNCoV2 compared to Comirnaty® in terms of neutralizing antibodies against the SARS-CoV-2 (Wuhan wild type) as the primary endpoint, and other variants of concern as secondary endpoints Bavarian Nordic A/S […]
continue readingBavarian Nordic Enters Multiple Vaccine Contracts with Governments in Response to Global Monkeypox Outbreak
A number of contracts of varying size have been signed Deliveries to start immediately aiming to ensure a rapid response to the current monkeypox outbreak Company upgrades its financial guidance for 2022 Bavarian Nordic A/S (OMX: BAVA) announced today the signing of a number of supply contracts with undisclosed countries for the Company’s smallpox […]
continue reading